Navigation Links
Aureus Pharma Releases AurPROFILER(R) - a New and Powerful Pharmacology Profiling Solution
Date:8/18/2008

PARIS, August 18 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions that accelerate life science discovery, announced the release today of the new software solution AurPROFILER(R).

AurPROFILER enables researchers to rapidly evaluate target, cell and drug profiles using bio-assays derived from the activity data found in Aureus Pharma's AurSCOPE Target Knowledge databases. AurPROFILER has been designed to work in conjunction with the just released AurSCOPE(R) Global Pharmacology Space and all of Aureus' drug target focused knowledge databases.

Compound profiling is routinely used by pharmaceutical researchers to evaluate the critical issues of drug target selectivity including off-target effects, polypharmacology and cytotoxicity. With easily interpretable graphics, AurPROFILER provides valuable insights to help better manage these issues by rapidly providing in-silico profiles. AurPROFILER results facilitate better discovery team decision making, and reduce risk to that streamline drug discovery projects. AurPROFILER was developed in collaboration with a pharmaceutical industry focus group consisting of several major pharmaceutical companies.

"After intensive development and customer validation, we are delighted to release AurPROFILER." said Jason Theodosiou, President and CEO of Aureus Pharma. "AurPROFILER is an example where the combination of Aureus' analysis capabilities and the high quality data within AurSCOPE Knowledge databases combine to bring additional value to researchers."

Aureus Pharma experts will demonstrate AurPROFILER at the American Chemical Society (ACS) meeting in Philadelphia, PA August 18th -21st.

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes as well as ADME/Tox topics. The information contained in the Aureus Pharma system is of primary importance to aid in lead discovery and optimization as well as to build predictive models. Aureus delivers its information in the AurSCOPE format. The AurSCOPE product line includes: AurSCOPE GPCR, AurSCOPE Ion Channel, AurSCOPE Kinase, AurSCOPE Nuclear Receptors, AurSCOPE Proteases and AurSCOPE Global Pharmacology Space. For further information on how Aureus Pharma helps researchers turn data into discovery visit http://www.aureus-pharma.com.

Media Contact

Mary E. Donlan, Ph.D.

Director of Marketing

Aureus Pharma

Phone:+33-1-40-18-57-59/+33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
2. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
3. QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels (TCA) ... to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... one of ACA’s member angel groups. It is the highest honor available for an ...
(Date:5/18/2016)... May 18, 2016 The Biotech industry ... not mean that there are no opportunities ahead. Today, ActiveWallSt.com ... (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... and Ophthotech Corp. (NASDAQ: OPHT ). Sign up ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, ... result of asthma complications.* Costing more than $56 billion in direct costs annually, ... , “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):